Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: Findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial

International Journal of Geriatric Psychiatry

Volumn 27, Issue 4, 2012, Pages 364-374

  Leoutsakos, Jeannie Marie S ^a,b   Muthen, Bengt O ^c   Breitner, John C S ^d   Lyketsos, Constantine G ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alzheimer; dementia; growth mixture models; NSAIDs; prevention

Indexed keywords

CELECOXIB; NAPROXEN; PLACEBO;

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DETERIORATION; HUMAN; ILLNESS TRAJECTORY; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COGNITION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NAPROXEN; PYRAZOLES; SULFONAMIDES;

EID: 80053383308     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2723     Document Type: Article

References (61)

1. AD2000 Collaborative Group, Bentham P, Gray R, Sellwood E, Hills R, Crome P, Raftery J,. 2008. Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. Lancet Neurol 7 (1): 41-49.
2. ADAPT Research Group. 2008. Cognitive function over time in the Alzheimer's disease anti-inflammatory prevention trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65 (7): 896-905.
3. ADAPT Research Group, Lyketsos CG, Breitner JC, et al,. 2007. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68 (21): 1800-1808. (Pubitemid 46791392)
4. Aisen PS, Schmeidler J, Pasinetti GM,. 2002. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 58 (7): 1050-1054. (Pubitemid 34298544)
5. Aisen PS, Schafer KA, Grundman M, et al,. 2003. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289 (21): 2819-2826. (Pubitemid 37430117)
6. Aizenstein HJ, Nebes RD, Saxton JA, et al,. 2008. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65 (11): 1509-1517.
7. Akiyama H, Barger S, Barnum S, et al,. 2000. Inflammation and Alzheimer's disease. Neurobiol Aging 21 (3): 383-421. (Pubitemid 30349107)
8. Amieva H, Le Goff M, Millet X, et al,. 2008. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol 64 (5): 492-498.
9. Arvanitakis Z, Grodstein F, Bienias JL, et al,. 2008. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 70 (23): 2219-2225.
10. Bäckman L, Jones S, Berger AK, Laukka EJ, Small BJ,. 2005. Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. Neuropsychology 19 (4): 520-531. (Pubitemid 41077134)
11. Bandeen-Roche K, Miglioretti DL, Zeger SL, Rathouz PJ,. 1997. Latent variable regression for multiple discrete outcomes. J Am Stat Assoc 92 (440): 1375-1386.
12. Bauer J, Konig G, Strauss S, et al,. 1991. In-vitro matured human microphages express Alzheimer's beta A4-amyloid precursor protein indicating synthesis microglial cells. FEBS Lett 282 (2): 335-340.
13. Bitting L, Naidu A, Cordell B, Murphy GM Jr., 1996. Beta-amyloid peptide secretion by a microglial cell line is induced by beta amyloid-(25-35) and lipopolysaccharide. J Biol Chem 271 (27): 16084-16089. (Pubitemid 26236222)
14. Braak H, Braak E,. 1997. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18 (4): 351-357. (Pubitemid 27435070)
15. Breitner JCS,. 2009. Treatment effects of NSAIDS related to stage of Alzheimer's pathogenesis: lessons from ADAPT. Alzheimers Dement 5 (4, SUPPL.ement): P144.
16. Breitner JCS, Haneuse SJPA, Walker R, et al,. 2009. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 72: 1899-1905.
17. Casellie RJ, Chen K, Lee W, Alexander GE, Reiman EM,. 2008. Correlating cerebral hypometablolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment. Arch Neurol 65 (9): 1231-1236.
18. Chen P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST, Ganguli M, et al,. 2001. Patterns of cognitive decline in presymptomatic Alzheimer disease: a prospective community study. Arch Gen Psychiatry 58 (9): 853-858. (Pubitemid 32979303)
19. Clark CM, Ewbank DC,. 1986. Performance of the dementia severity rating scale: a caregiver questionnaire for rating severity in Alzheimer disease. Alzheimer Dis Assoc Disord 10: 31-39.
20. Diggle PJ, Heagerty P, Liang K-Y, Zeger SL,. 2002. Analysis of Longitudinal Data, 2nd edn. Oxford University Press, Inc: New York, NY.
21. Elkins JS, Longstreth WT Jr, Manolio TA, et al,. 2006. Education and the cognitive decline associated with MRI-defined brain infarct. Neurology 67 (3): 435-440. (Pubitemid 44214967)
22. Fennema-Notestine C, McEvoy L, Hagler DJ, et al,. 2009. Structural neuroimaging in the detection and prognosis of pre-clinical and early AD. Behav Neurol 21: 3-12.
23. Fripp J, Bourgeat P, Acosta O, et al,. 2008. Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. Neuroimage 43 (3): 430-439.
24. Greenbaum PE, Del Boca FK, Darkes J, Wang CP, Goldman MS,. 2005. Variation in the drinking trajectories of freshmen college students. J Consult Clin Psychol 73 (2): 229-238. (Pubitemid 40446378)
25. Hayden KM, Zandi PP, Khachaturian AS, et al,. 2007. Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology 69 (3): 275-282. (Pubitemid 47205690)
26. Hoozemans JJM, Rozemuller JM, van Hastert ES, Veerhuis R, Eikelenboom P,. 2008. Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. Curr Pharm Des 14: 1419-1427. (Pubitemid 351982549)
27. Hoozemans JJM, Veerhuis R, Rozemuller JM, Eikelenboom P,. 2011. Soothing the inflamed brain: effect of non-steroidal anti-inflammatory drugs on Alzheimer's disease pathology. CNS Neurol Disord Drug Targets 10 (1): 57-67.
28. Howieson DB, Carlson NE, Moore MM, et al,. 2008. Trajectory of mild cognitive impairment onset. J Int Neuropsychol Soc 14 (2): 192-198. (Pubitemid 351279998)
29. Huberman M, Shalit F, Ruth-Deri I, et al,. 1994. Correlation of cytokine secretion by mononuclear cells of Alzheimer patients and their disease stage. J Neuroimmunol 52 (2): 147-152. (Pubitemid 24223248)
30. de Jong D, Jansen R, Hoefnagels W, et al,. 2008. No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. PLoS ONE 3 (1): e1475.
31. Jung T, Wickrama KAS,. 2008. An introduction to latent class growth analysis and growth mixture modeling. Soc Personal Psychol Compass 2: 302-317.
32. Kreuter F, Muthen B,. 2008. Analyzing criminal trajectory profiles: Bridging multilevel and group-based approaches using growth mixture modeling. J Quant Criminol 24: 1-31.
33. Leoutsakos JM, Zandi PP, Bandeen-Roche K, Lyketsos CG,. 2010. Searching for valid psychiatric phenotypes: discrete latent variable models. Int J Meth Psychiatr Res 19 (2): 63-73.
34. Lyketsos CG, Szekely CA, Mielke MM, Rosenberg PB, Zandi PP,. 2008. Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies. Int Psychogeriatr 20 (5): 871-889.
35. Mackenzie IR, Hao C, Munoz DG,. 1995. Role of microglia in senile plaque formation. Neurobiol Aging 16 (5): 797-804.
36. Mrak RZ, Griffin WS,. 2005. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 26 (3): 349-354. (Pubitemid 40082718)
37. Muthén B, Asparouhov T,. 2009. Growth mixture modeling: analysis with non-Gaussian random effects. In Longitudinal Data Analysis, Fitzmaurice G, Davidian M, Verbeke G, Molenberghs G, (eds). Chapman & Hall/CRC Press: Boca Raton, FL; 143-165.
38. Muthén B, Brown H,. 2009. Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling. Stat Med 28: 3363-3385.
39. Muthen B, Brown HB, Masyn K, et al,. 2002. General growth mixture modeling for randomized preventive trials. Biostatistics 3 (4): 459-475.
40. Nylund KL, Asparouhov T, Muthen BO,. 2007. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Struct Equ Modeling 14 (4): 535-569.
41. Paresce DM, Chung H, Maxfield FR,. 1997. Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells. J Biol Chem 272 (46): 29390-29397. (Pubitemid 27498234)
42. Reiman EM, Caselli RJ, Yun LS, et al,. 1996. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 334 (12): 752-758. (Pubitemid 26089356)
43. Reines SA, Block GA, Morris JC, et al,. 2004. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62 (1): 66-71. (Pubitemid 38082872)
44. Rogers J, Kirby LC, Hempelman SR, et al,. 1993. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43 (8): 1609-1611. (Pubitemid 23230557)
45. Rojo LE, Fernandez JA, Maccioni AA, Jimenez JM, Maccioni RB,. 2008. Neuroinflammation: implication for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 39 (1): 1-16. (Pubitemid 350192021)
46. Sasaki A, Yamaguchi H, Ogawa A, Sugihara S, Nakuzato Y,. 1997. Microglial activation in early stages of amyloid beta protein deposition. Acta Neuropathol 94 (4): 316-322. (Pubitemid 27450110)
47. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N,. 1999. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 53 (1): 197-201. (Pubitemid 29329671)
48. Shaffer LM, Dority MD, Gupta-Bansal R, et al,. 1995. Amyloid beta protein (A beta) removal by neuroglial cells in culture. Neurobiol Aging 16 (5): 737-745.
49. Small BJ, Backman L,. 2007. Longitudinal trajectories of cognitive change in preclinical Alzheimer's disease: a growth mixture modeling analysis. Cortex 43: 826-834. (Pubitemid 47517036)
50. Small BJ, Fratiglioni L, Viitanen M, Winblad B, Bäckman L,. 2000. The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample. Arch Neurol 57 (6): 839-844. (Pubitemid 30397186)
51. Soininen H, West C, Robbins J, Niculescu L,. 2007. Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement Geriatr Cogn Disord 23 (1): 8-21. (Pubitemid 46005786)
52. Szekely CA, Thorne JE, Zandi PP, et al,. 2004. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23 (4): 159-169. (Pubitemid 38980441)
53. Szekely CA, Breitner JC, Fitzpatrick AL, et al,. 2008. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology 70 (1): 17-24.
54. Szekely CA, Green RC, Breitner JC, et al,. 2008. No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 70 (24): 2291-2298.
55. Teng EL, Chui HC,. 1987. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 48 (8): 314-318. (Pubitemid 17138128)
56. Terrera GM, Brayne C, Matthews F, CC75C Study Collaboration Group. 2009. One size fits all? Why we need more sophisticated analytical methods in the explanation of trajectories of cognition in older age and their potential risk factors. Int Psychogeriatr 22 (2): 291-299.
57. Thal LJ, Ferris SH, Kirby L, et al,. 2005. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30 (6): 1204-1215. (Pubitemid 40720980)
58. Vlad SC, Miller DR, Kowall NW, Felson DT,. 2008. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70 (19): 1672-1677. (Pubitemid 351644133)
59. Wimo A, Jonsson L, Winblad B,. 2006. An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord 21 (3): 175-181. (Pubitemid 43201328)
60. Wisniewski HM, Wegiel J,. 1994. The role of microglia in amyloid fibril formation. Neuropathol Appl Neurobiol 20 (2): 192-194. (Pubitemid 24123560)
61. Wyss-Coray T,. 2006. Inflammation in Alzheimer disease: driving force, bystander, or beneficial response? Nat Med 12 (9): 1005-1015. (Pubitemid 44353380)